Contact

EATRIS ANNOUNCES NOVEL PUBLIC-PRIVATE COLLABORATION FOR IMAGING METHOD DEVELOPMENT IN INFLAMMATORY DISEASES

International multi-site collaboration hub will implement new clinical imaging tools and deliver several projects per year with enhanced speed and throughput

Amsterdam, The Netherlands, June 4, 2018 -  The European Infrastructure for Translational Medicine (EATRIS) has formed a collaboration with GlaxoSmithKline (GSK) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases.

Read more...

iPEPS Biotech Startup Competition

The iPEPS innovation accelerator and Scientist.com are launching a call for biotech startups developing a novel therapeutic and/or diagnostic approach with a main focus on central nervous system (CNS) diseases (neuro-oncology, psychiatry, neurological disorders or preventive health).

Apply now until July 16th, and get awarded:

  • Up to 6 months office/lab spaces at iPEPS
  • Up to $10,000 in research services through Scientist.com marketplace (to be used within one year)
  • Consulting with experts in preclinical/clinical development to build out your TPP (target product profile).

The winner of this competition and the runner-up will be announced at the end of September and will benefit of iPEPS mentoring to fast track the development of their projects in one of the most thriving research and innovation ecosystem in Paris.

bandeau AAP iPEPS 2018

Maladie d’Alzheimer : un rôle protecteur des dégénérescences neurofibrillaires ?

​Les larges agrégats de protéines Tau observés dans les neurones des personnes atteintes de la maladie d’Alzheimer sont considérés comme étant au moins partiellement à l’origine de la maladie. Une étude conduite par des chercheurs de MIRCen (Institut de biologie François Jacob/CEA, NeurATRIS) suggère au contraire que ces dégénérescences neurofibrillaires (DNF) joueraient un rôle protecteur. 

Read more...

Plasma Amyloid is modulated by age and seasonal rhythms in mouse lemur primates

Accumulation of amyloid-β (Aβ) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. There is increasing interest in measuring levels of plasma Aβ since this could help in diagnosis of brain pathology. However, the value of plasma Aβ in such a diagnosis is still controversial and factors modulating its levels are still poorly understood.

Read more...